Sanofi: agreement with France's Voluntis on diabetes app.

(CercleFinance.com) - Sanofi said on Tuesday that it has signed with France's Voluntis a non-exclusive agreement to deliver digital insulin titration solutions, featuring a mobile phone application.


The app, designed to help improve decision-making and self-management of type-2 diabetes for people treated with basal insulin, has received FDA clearance and the CE mark in 2016.

As a reminder, Sanofi and Voluntis' alliance began in 2011 with the development of Diabeo, a software medical device that helps people with diabetes in France to manage their treatment.

Sanofi also said on Tuesday that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Sanofi Genzyme's investigational treatment for atopic dermatitis (AD) a positive scientific opinion.

The decision means that eligible adults with severe AD can access Sanofi Genzyme's dupilumab before the drug is granted marketing authorisation in the UK.

Copyright (c) 2017 CercleFinance.com. All rights reserved.